Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06750432 · ClinicalTrials.gov registry record · Phase 1

PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD)

A Phase 1 study of Alzheimer Disease, Early Onset, sponsored by ProMis Neurosciences.

Active
Registry status
Phase 1
Development phase
144
Enrollment target
20
Study locations

NCT06750432: Active Phase 1 study of Alzheimer Disease, Early Onset, sponsored by ProMis Neurosciences.

NCT06750432 is a Phase 1 study of Alzheimer Disease, Early Onset that is active but no longer recruiting, run by ProMis Neurosciences. The registered enrollment target is 144 participants, below the 1,476-participant average among 11 other Alzheimer Disease, Early Onset trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06750432, a Phase 1 study of Alzheimer Disease, Early Onset, is active but no longer recruiting, sponsored by ProMis Neurosciences.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
144 participants
Enrollment target
20
Study locations

Study Summary

This Phase 1b study aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of multiple IV infusions of PMN310 in patients with early Alzheimer's disease.

Primary Outcome

Number and severity of adverse events

Conditions Studied

Alzheimer Disease, Early Onset

Interventions

  • DRUG Placebo
  • DRUG PMN310

Study Locations (20)

Florida

  • JEM Research Institute - Atlantis
  • Quantum Laboratories - Deerfield Beach
  • Brain Matters Research - Delray Beach
  • Finlay Medical Research - Miami
  • Gonzalez MD and Aswad MD Health Services, Optimus U Corp - Miami
  • Renstar Medical Research - Ocala
  • Charter Research - Orlando
  • Alzheimer's Research and Treatment Center - Stuart
  • Charter Research - The Villages
  • Alzheimer's Research and Treatment Center - Wellington
  • Conquest Research, LLC - Winter Park

California

  • Irvine Center for Clinical Research - Irvine
  • Healthy Brain Research - Long Beach

Georgia

  • Columbus Memory Center, LLC - Columbus
  • CenExel iResearch, LLC - Decatur

Massachusetts

  • Headlands Eastern MA LLC - Plymouth

New Jersey

  • Advanced Memory Research Institute of NJ - Toms River

New York

  • Alzheimer's Disease Research Center - Albany

North Carolina

  • Flourish Research - Matthews

Ohio

  • Neuro Behavioral Clinical Research, Inc. - North Canton

Trial Details

FieldValue
Enrollment Target 144 participants
Start Date 2024-12-13
Est. Completion 2026-12
Phase Phase 1
ProMis Neurosciences

2 total trials

What the registry record for NCT06750432 still lists

NCT06750432 is an interventional study that assigns participants to a tested intervention. The registered 144 participants enrollment target is mid-sized for trials with a published cap, below the 1,476-participant average among 11 other Alzheimer Disease, Early Onset trials with a reported enrollment target (90% lower).

The record links to 1 condition, with Alzheimer Disease, Early Onset appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06750432 names 20 study sites across 8 states, led by Florida, California, Georgia.

Frequently Asked Questions

What is clinical trial NCT06750432 about?

NCT06750432 is a clinical study titled "PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD)". This Phase 1b study aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of multiple IV infusions of PMN310 in patients with early Alzheimer's disease.

What is the current status of trial NCT06750432?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 144 participants. The study started on 2024-12-13. Estimated completion is 2026-12.

What conditions does trial NCT06750432 study?

This clinical trial studies the following conditions: Alzheimer Disease, Early Onset.

What interventions are being tested in trial NCT06750432?

The interventions under investigation include: Placebo (DRUG), PMN310 (DRUG).

Who is sponsoring clinical trial NCT06750432?

This trial is sponsored by ProMis Neurosciences, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06750432 being conducted?

This trial has 20 study locations across California, Florida, Georgia, Massachusetts, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Alzheimer Disease, Early Onset

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06750432's enrollment target sits among peer trials

144 5th of 11 higher than 7 of 11 other Alzheimer Disease, Early Onset trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Alzheimer Disease, Early Onset trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01861106 · 144 participants · Phase 2

    Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations

  • NCT03482245 · 144 participants · NA

    The Role of Circadian Clock Proteins in Innate and Adaptive Immunity

  • NCT03504683 · 144 participants · NA

    MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes

  • NCT03905603 · 144 participants · Early Phase 1

    Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT06750432, the US trial registry maintained by the National Library of Medicine. NCT06750432 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.